DESTINATION STARTUP

Laporte Immunotherapeutics

One-Sentence Summary of What You Do: Laporte Immunotherapeutics, Inc. is a pre-clinical stage biopharmaceutical company developing transformative immune-based therapies for upper respiratory and eye infections, using immune stimulatory nanoparticles to activate immune defenses in the nose and eye.

Affiliated Institution: Colorado State University

Have you formed a company yet? Yes

Funding/Financing: Grant Funding, Direct/Indirect University Support, Angel Funding (including Self or Friends/Family)

Please describe your company and the problem you are trying to solve: Laporte Immunotherapeutics, Inc. is a pre-clinical stage biopharmaceutical company developing transformative immune-based therapies for upper respiratory and eye infections, using immune stimulatory nanoparticles to activate immune defenses in the nose and eye. The technology platform provides a unique approach as a broadly active preventative or therapeutic option to prevent or treat a wide variety of viral, bacterial, and fungal pathogens infecting the upper respiratory tract and eye. The technology consists of highly active nanoparticles designed to deliver immune-stimulatory molecules into key protective cells in the nose and eyes. The technology has demonstrated broad protective and therapeutic efficacy in relevant large animal infection models, including cattle, horses, dogs, and cats. Significant market opportunities include treatment of cold and sinus infections and ocular infections with chronic viruses such as herpes and acute infections including adenovirus (Pink Eye). Recent animal studies have revealed significant activity in preventing nasal infections with the Covid-19 virus, which opens large opportunities for pandemic protection. Laporte Immunotherapeutics holds an exclusive license for all uses from the Colorado State University Research Foundation (CSURF) for patents and applications covering composition of matter and uses of the drug. The company will continue to develop its intellectual property estate to support technology licensing and asset sales initiatives which are key to generating a return for our shareholders. -Issued patent (US 10,512,687) Dec 24, 2019 -Multiple provisional applications -Exclusive license from Colorado State University Research Foundation -Composition and methods protected in patent; additional CIPs filed for specific therapeutic targets.

What is/was your go-to-market strategy? Small, entrepreneurial pharmaceutical companies rarely take their products all the way to market. Therefore, our immediate customer would be a large pharmaceutical company that will license or purchase the rights and complete development, manufacture the drug and handle distribution. Our primary go-to-market strategy is therefore to develop the drug to the point a large pharma will acquire or license the technology. Laporte will work to establish early efficacy data and to reduce risks for our products and to then seek to license or sell indication specific assets to established pharmaceutical companies. Our approach is fully scalable until we exhaust indications for our technology platform, at which time, our shareholders will have received a strong return on investment. We are currently negotiating sponsored, independent proof-of-concept studies and exclusive license rights with a multinational animal health company for both companion and food animal use. On the human ocular side, we have relationships with ophthalmologists at CU Anschutz Medical Campus and are beginning to plan clinical trials for our eye antiviral (herpes simplex and pink eye). On the human upper respiratory side, we have very encouraging animal data backed by peer reviewed publications that can support indications including chronic sinusitis and therapeutic or prophylactic use against numerous other viral and bacterial pathogens. For human respiratory and ocular indications, Laporte is actively working to attract large pharma development partners and have had early stage discussions with two multinational companies. These and other commercial efforts will continue as drug development continues.

How will/do you generate revenue? Revenue will be generated from technology licensing and asset sales in human and animal health markets. Entering into milestone based agreements where proving certain levels of product performance results in significant cash payments to Laporte and subsequent royalty or asset sale payments to Laporte presents the opportunity for strong return on investment for Laporte and our shareholders. The three main areas we expect to generate revenue include: - Animal health development and royalty - Human ophthalmic indications - Human respiratory viral prophylactic indications - Human squamous cell carcinoma therapeutic Laporte Immunotherapeutics does not at present intend to bring products to market directly but will instead out-license the technologies or sell the Company outright to a large pharmaceutical company in the next 5 years. Our top targets with large infectious disease franchises with multiple expressing interest and include Pfizer, Merck, GSK, Sanofi, Novartis, and Gilead. An accepted business model when small innovative companies possess valuable new drug IP and technologies is to license the IP and know how to a much larger pharmaceutical company to complete development and provide distribution. It is important for the small company to produce strong early human safety and efficacy data in advance of finalizing an agreement since strong data will lead to optimal product licensing terms. We will work to develop this data demonstrating basic safety and early clinical efficacy in humans while interacting with potential licensing partners.

How will this showcase benefit your company or technology? Securing early stage funding which will be used to reduce the known risks of our early drug candidate is key to securing future larger scale funding and engaging acquisition partners. this money will be used directly to reduce to risk of future investment by demonstrating efficacy and safety in select animal models, a critical next step in building a successful company. 1- This Showcase will aid Laporte in better engaging pharma partners to fund continued development of the drug resulting in increases in valuation for Laporte and a more attractive technology portfolio. 2- This exposure and feedback will enable Laporte to better compete for federal grant money since the introductions generated will make help to attract the talent and supporters needed to win grant money. 3- This Showcase will provide introductions to potential investors in future Series A investments. 4- Ultimately, this exposure is one small step towards the ultimate goal of acquisition by a large pharma partner bringing our product to market, building the pharmaceutical industry in Colorado and generating healthy returns for our shareholders.

Who are the members of your team and why is this the right team to get the job done?

- Steve Tyrrell, CEO and brings >25 years of entrepreneurial leadership experience in healthcare product markets, introducing new ideas to markets and leading diverse teams from the earliest stages to market.
- Steve Dow DVM, PhD, CSO and Professor in the Department of Clinical Sciences at Colorado State University. Dr. Dow is a prolific investigator and has successfully moved discoveries from his labs to market with Zelnate.
- Lyndah Chow, Ph.D. is a Research Scientist in Dr. Dow's lab and is actively involved in studies to elucidate the mechanisms of action of this immunotherapy platform technology Laporte currently has four key groups of advisors; we are an Innosphere client company, our corporate legal advisors, patent attorney and have recently completed on boarding and we have engaged a drug development company CSSi and are supported by seasoned drug development talent.
- CSSi has agreed to accept $45,000 in company issued warrants as cash in kind for the initial $50,000 in services. We have engaged a corporate law firm, SAGE Law Group in Boulder to advise on investor and corporate matters and are working with Polsinelli for patent protection. Laporte will utilize an established Contract Development and Manufacturing Organization (CDMO) for all regulated manufacturing and are currently interviewing partners. Research use product is currently produced in the laboratories of Dr. Steven Dow at Colorado State University but this will not be used for regulated studies or for clinical use in humans or animals.